358 related articles for article (PubMed ID: 15313899)
1. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas.
Blázquez C; González-Feria L; Alvarez L; Haro A; Casanova ML; Guzmán M
Cancer Res; 2004 Aug; 64(16):5617-23. PubMed ID: 15313899
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.
Kimura Y; Sumiyoshi M; Baba K
Cancer Sci; 2008 Oct; 99(10):2083-96. PubMed ID: 19016770
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis.
Sonoda Y; Kanamori M; Deen DF; Cheng SY; Berger MS; Pieper RO
Cancer Res; 2003 Apr; 63(8):1962-8. PubMed ID: 12702589
[TBL] [Abstract][Full Text] [Related]
4. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.
Weigand M; Hantel P; Kreienberg R; Waltenberger J
Angiogenesis; 2005; 8(3):197-204. PubMed ID: 16328160
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
6. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
[TBL] [Abstract][Full Text] [Related]
7. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
Jung MH; Lee SH; Ahn EM; Lee YM
Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
9. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
11. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.
Lamszus K; Ulbricht U; Matschke J; Brockmann MA; Fillbrandt R; Westphal M
Clin Cancer Res; 2003 Apr; 9(4):1399-405. PubMed ID: 12684411
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
13. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes.
Aghi M; Cohen KS; Klein RJ; Scadden DT; Chiocca EA
Cancer Res; 2006 Sep; 66(18):9054-64. PubMed ID: 16982747
[TBL] [Abstract][Full Text] [Related]
14. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis.
Scaldaferri F; Vetrano S; Sans M; Arena V; Straface G; Stigliano E; Repici A; Sturm A; Malesci A; Panes J; Yla-Herttuala S; Fiocchi C; Danese S
Gastroenterology; 2009 Feb; 136(2):585-95.e5. PubMed ID: 19013462
[TBL] [Abstract][Full Text] [Related]
15. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
Hazarika S; Dokun AO; Li Y; Popel AS; Kontos CD; Annex BH
Circ Res; 2007 Oct; 101(9):948-56. PubMed ID: 17823371
[TBL] [Abstract][Full Text] [Related]
16. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas.
Al-Dissi AN; Haines DM; Singh B; Kidney BA
Vet Pathol; 2007 Nov; 44(6):823-30. PubMed ID: 18039895
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt.
Nishi J; Minamino T; Miyauchi H; Nojima A; Tateno K; Okada S; Orimo M; Moriya J; Fong GH; Sunagawa K; Shibuya M; Komuro I
Circ Res; 2008 Aug; 103(3):261-8. PubMed ID: 18583712
[TBL] [Abstract][Full Text] [Related]
19. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
Argyriou AA; Giannopoulou E; Kalofonos HP
Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
